Suraksha Diagnostic Ltd Reports Strong Q1 FY27, Appoints New CFO

Consolidated PAT: ₹12.85 crore | Standalone PAT: ₹12.58 crore

Reader Takeaway: Consistent YoY profit growth offers positive outlook; however, a step-down subsidiary's legal dispute poses a concern.

What just happened

Suraksha Diagnostic Limited announced its financial results for the first quarter of fiscal year 2027 (Q1 FY27), ending June 30, 2026. The company reported a consolidated profit after tax (PAT) of ₹12.85 crore, a significant increase from ₹9.18 crore in the same quarter last year. Standalone PAT also saw robust growth, rising to ₹12.58 crore from ₹9.85 crore year-on-year.

In addition to the financial performance, Suraksha Diagnostic announced the appointment of Mr. Dinesh Gupta as its new Chief Financial Officer (CFO) and Group CFO, effective August 24, 2026. The company also fixed September 15, 2026, as the record date for its dividend payout for the financial year ended March 31, 2026, and scheduled its 21st Annual General Meeting (AGM) for September 22, 2026.

Why this matters

The positive financial results indicate the company's ability to grow its earnings consistently. The appointment of a new CFO signals potential shifts in financial strategy or management focus. The dividend announcement is a direct benefit to shareholders, while the AGM is a key event for corporate governance.

The backstory

Suraksha Diagnostic is a diagnostic services provider. This Q1 FY27 performance follows a period where the company has focused on expanding its services and managing its operations effectively. The financial details show a healthy uptrend in both revenue and profitability over the last year.

What changes now

Shareholders can anticipate the upcoming dividend and participate in the AGM. The new CFO's tenure will likely bring new perspectives to the company's financial management. The ongoing legal dispute with the Government of Meghalaya concerning a step-down subsidiary remains a point to monitor.

Risks to watch

The primary risk highlighted is the ongoing legal dispute involving a step-down subsidiary and the Government of Meghalaya. The company's total exposure is ₹3.94 crore, with a provision of ₹0.81 crore made as of June 30, 2026. Arbitration proceedings are underway.

Peer comparison

While specific peer data was not provided in the filing, Suraksha Diagnostic's reported year-on-year growth in both revenue and PAT suggests a competitive performance within the diagnostic sector.

Context metrics (time-bound)

• Q1 FY27 Standalone Revenue: ₹84.09 crore (up from ₹70.28 crore in Q1 FY26)
• Q1 FY27 Standalone PAT: ₹12.58 crore (up from ₹9.85 crore in Q1 FY26)
• Q1 FY27 Consolidated Revenue: ₹87.65 crore (up from ₹72.59 crore in Q1 FY26)
• Q1 FY27 Consolidated PAT: ₹12.85 crore (up from ₹9.18 crore in Q1 FY26)
• Subsidiary Exposure (as of June 30, 2026): ₹3.94 crore
• Subsidiary Provision (as of June 30, 2026): ₹0.81 crore

What to track next

Investors should track the progress of the arbitration proceedings related to the Meghalaya dispute and any further updates on the new CFO's strategic initiatives. The company's ability to sustain its growth trajectory in upcoming quarters will also be crucial.